BR112019008565A2 - distribuição do agente ativo na mucosa - Google Patents

distribuição do agente ativo na mucosa

Info

Publication number
BR112019008565A2
BR112019008565A2 BR112019008565A BR112019008565A BR112019008565A2 BR 112019008565 A2 BR112019008565 A2 BR 112019008565A2 BR 112019008565 A BR112019008565 A BR 112019008565A BR 112019008565 A BR112019008565 A BR 112019008565A BR 112019008565 A2 BR112019008565 A2 BR 112019008565A2
Authority
BR
Brazil
Prior art keywords
active agent
mucosa
agent distribution
composition
distribution
Prior art date
Application number
BR112019008565A
Other languages
English (en)
Inventor
Worth Carol
Baride Kalpana
Original Assignee
Suda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904449A external-priority patent/AU2016904449A0/en
Application filed by Suda Ltd filed Critical Suda Ltd
Publication of BR112019008565A2 publication Critical patent/BR112019008565A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método para aumentar a penetração de agentes ativos através de membranas mucosas, o método compreendendo a etapa de: a) administrar a um sujeito em necessidade uma composição compreendendo: i) um ou mais hidrótropos em uma quantidade total inferior a 15% em peso de a composição; e ii) um agente ativo com um coeficiente de partição (logp) ou coeficiente de distribuição (logd) entre 0 e 5.
BR112019008565A 2016-10-31 2017-10-30 distribuição do agente ativo na mucosa BR112019008565A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016904449A AU2016904449A0 (en) 2016-10-31 Mucosal Active Agent Delivery
PCT/AU2017/051193 WO2018076074A1 (en) 2016-10-31 2017-10-30 Mucosal active agent delivery

Publications (1)

Publication Number Publication Date
BR112019008565A2 true BR112019008565A2 (pt) 2019-07-09

Family

ID=62023155

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008565A BR112019008565A2 (pt) 2016-10-31 2017-10-30 distribuição do agente ativo na mucosa

Country Status (10)

Country Link
US (1) US11458201B2 (pt)
EP (1) EP3532068A4 (pt)
JP (1) JP2019536769A (pt)
KR (1) KR20190082803A (pt)
CN (1) CN109996547A (pt)
AU (1) AU2017351744A1 (pt)
BR (1) BR112019008565A2 (pt)
CA (1) CA3041112A1 (pt)
MX (1) MX2019004894A (pt)
WO (1) WO2018076074A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05221857A (ja) * 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
WO1997019593A1 (en) * 1995-11-28 1997-06-05 Wider Michael D Antimicrobial composition and methods of use therefor
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
JP2000119198A (ja) * 1998-10-16 2000-04-25 Eisai Co Ltd 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
JP2002041452A (ja) 2000-07-27 2002-02-08 Hitachi Ltd マイクロプロセッサ、半導体モジュール及びデータ処理システム
WO2002050365A1 (en) * 2000-12-20 2002-06-27 Unilever N.V. Fabric cleaning system
US6660211B2 (en) * 2001-04-23 2003-12-09 Kimberly-Clark Worldwide, Inc. Methods of making biodegradable films having enhanced ductility and breathability
US20100204323A1 (en) * 2004-12-09 2010-08-12 The Dial Corporation Antimicrobial compositions comprising organic acid esters and methods for reducing virus and bacterial populations using such compositions
JP5514270B2 (ja) * 2005-09-13 2014-06-04 ロート製薬株式会社 アシタザノラスト含有組成物
RU2008151178A (ru) * 2006-05-24 2010-06-27 Дзе Дайл Корпорейшн (Us) Способы и изделия, обладающие сильным противовирусным и противобактериальным действием
MX2008015455A (es) * 2006-06-05 2009-01-12 Dial Corp Metodos y articulos que tienen una alta eficacia antiviral y antibacterial.
EP2068831A4 (en) * 2006-07-28 2010-07-21 Novadel Pharma Inc ANTIMIGRANEOUS MUNDSPRAY FORMULATIONS AND CORRESPONDING METHODS
US20080280947A1 (en) * 2007-05-10 2008-11-13 Blondino Frank E Anti-insomnia compositions and methods
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
EP2575765B1 (en) 2010-06-07 2018-12-05 Suda Ltd Oral spray formulations and methods for administration of sildenafil citrate
US9186321B2 (en) * 2011-12-05 2015-11-17 Suda Ltd. Oral spray formulations and methods for administration of sildenafil
KR102261301B1 (ko) * 2012-10-12 2021-06-07 로레알 적어도 하나의 하이드로트로프 및 적어도 하나의 활성제을 포함하는 화장용 조성물
US20150250791A1 (en) 2014-03-06 2015-09-10 Bhaskara Rao Jasti Combining sildenafil with caffeine in an oral disintegrating dosage form
US20160166543A1 (en) * 2014-12-10 2016-06-16 Hemant N. Joshi Stable combination oral liquid formulation of melatonin and an antihistaminic agent

Also Published As

Publication number Publication date
JP2019536769A (ja) 2019-12-19
MX2019004894A (es) 2019-06-20
CN109996547A (zh) 2019-07-09
CA3041112A1 (en) 2018-05-03
EP3532068A1 (en) 2019-09-04
US11458201B2 (en) 2022-10-04
EP3532068A4 (en) 2020-04-29
US20190282697A1 (en) 2019-09-19
KR20190082803A (ko) 2019-07-10
WO2018076074A1 (en) 2018-05-03
AU2017351744A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
AR100925A1 (es) Composiciones orales que contienen fuentes de ión de zinc, estaño y fluoruro
AR100928A1 (es) Composiciones orales que contienen iones de metales
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
MX2017010220A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
BR112014016668A8 (pt) composições para cuidados pessoais contendo silicone iônico e agente formador de filme
MX2019007186A (es) Composiciones para el cuidado bucal.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
AR094012A1 (es) Composiciones estables con peroxido para el cuidado oral
BR112015012808A2 (pt) composição de cuidado oral
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017022971A2 (pt) aperfeiçoamentos em ou com relação a compostos orgânicos
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
BR112017028137A2 (pt) agente terapêutico para fibrose
BR112018068116A2 (pt) película transmucosal para administração de montelucaste
BR112015002004A2 (pt) isolamento de mutantes melhoradores de tráfego de proteínas transportadoras de medicamentos
BR112019006087A2 (pt) composição de cuidados bucais e método para beneficiar dentes de um indivíduo
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2746 DE 22-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.